Results 261 to 270 of about 617,754 (317)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Cure rate estimation with insufficient follow-up: A median-based bootstrap correction approach. [PDF]

PLoS One
Ibi Y, Omori T.
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Covalent FAPI Imaging-Guided Precision Surgery in Patients with Medullary Thyroid Carcinoma: A Phase II Clinical Trial. [PDF]

Clin Cancer Res
Kong Z, Liu Y, Lin YS, Li Z, Cui XY, Liu S, Zhang X, Li R, Yang Y, Sun Y, Nie Y, Zhang Z, An C, Ni S, Zhu Y, Liu Z, Wang J, Liu S.   +17 more
europepmc   +1 more source

Establishing an assay to evaluate d‐amino acid oxidase enzyme kinetics and inhibition using WST‐8 redox dye

FEBS Open Bio, EarlyView.
This study investigated a novel WST‐8‐based assay for evaluating d‐Amino acid oxidase (DAO) inhibitors. We confirmed its effectiveness using known inhibitors and found that uremic toxins possess relatively weak inhibitory activity compared to existing drugs.
Kahoko Miyake, Yuki Enoki, Yuka Nakazawa, Kazuaki Taguchi, Kazuaki Matsumoto   +4 more
wiley   +1 more source

Comparative effectiveness of moxibustion-based combination therapies for lumbar disc herniation: a systematic review and network meta-analysis of 50 randomized trials. [PDF]

Front Neurol
Du D, Wang S, Wang S, Sun H, Shan Y.
europepmc   +1 more source

Comparison of the Efficacy and Safety of Intravenous Ceftazidime-Avibactam and Intrathecal/Intraventricular Polymyxin B Sulfate in the Treatment of CNS Infections Caused by KPC-<i>Kp</i> in Neurosurgical Patients: A Single-Center Prospective Observational Study. [PDF]

Antibiotics (Basel)
Wang MH, Li NY, Chen W, Fan YX, Li WZ, Chen YR, Hu J, Wu G, Zhang J, Yang L.   +9 more
europepmc   +1 more source

Synovial structures - cure or no cure?

, 2011
openaire   +2 more sources

Fad diets, schizophrenia, and politics: An internet frenzy that highlights broader concerns. [PDF]

PLOS Ment Health
Locke T.
europepmc   +1 more source